Evolving Treatment Paradigm for Follicular Lymphoma演化范式的滤泡性淋巴瘤的治疗课件.pptVIP

下载本文档

5
0
约9.21万字
约 52页
2018-06-22 发布于贵州
举报
版权申诉

Evolving Treatment Paradigm for Follicular Lymphoma演化范式的滤泡性淋巴瘤的治疗课件.ppt

1、本文档共52页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Evolving Treatment Paradigm for Follicular Lymphoma演化范式的滤泡性淋巴瘤的治疗课件

Evolving Standards of Care in Non-Hodgkins Lymphoma * * VA Indolent Lymphoma v4 * Philip J. Bierman, M.D. * B, bendamustine; CR, complete response; FL, follicular lymphoma; ORR, overall response rate; PD, progressive disease; PR, partial response; R, rituximab; SD, stable disease; V, bortezomib. ? The overall response rate in this trial was 86%, which compared favorably with an overall response rate of 59% observed with the last previous therapy for these patients. ? For more information, go online to: /Oncology/Conference%20Coverage/Hematology%202009/Tracks/Lymphomas/Capsules/933.aspx ? Evolving Standards of Care in Non-Hodgkins Lymphoma * * VA Indolent Lymphoma v4 * Philip J. Bierman, M.D. * NHL, non-Hodgkin’s lymphoma; ORR, overall response rate; PFS, progression-free survival. ? Another newer agent with activity in the relapsed/refractory setting is lenalidomide. The use of lenalidomide for relapsed and refractory indolent lymphomas was tested in a multi-institutional phase?II trial. Lenalidomide was administered at 25 mg daily on Days 1-21 of a 28-day cycle. ? Evolving Standards of Care in Non-Hodgkins Lymphoma * * VA Indolent Lymphoma v4 * Philip J. Bierman, M.D. * AE, adverse event; CR, complete response; CRu, unconfirmed complete response; DOR, duration of response; NHL, non-Hodgkin’s lymphoma; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. ? This agent demonstrated activity with a 23% overall response rate. Evolving Standards of Care in Non-Hodgkins Lymphoma * * VA Indolent Lymphoma v4 * Philip J. Bierman, M.D. * * Q, every; TTP, time to progression. ? The combination of lenalidomide and rituximab is being tested in a CALGB trial for patients with previously treated follicular lymphoma. The first arm, rituximab alone, has closed, but the other arms examining lenalidomide alone and lenalidomide plus rituximab are still accruing patients. ? Evolving Standards of Care in Non-Ho